Indivior Pharmaceuticals, Inc.

INDV · Nasdaq · ·

Confronta

28,15 USD+2,6%chiusura 2 nov

Dati fino al 30 settembre 2026, dal 10-Q depositato il 29 ottobre 2026

1M: +6,2%
3M: -7,0%

Azioni Indivior Pharmaceuticals, Inc. (INDV) — è una buona azienda? — InspectStocks

Indivior Pharmaceuticals, Inc.

INDV · Nasdaq · ·

Confronta

28,15 USD+2,6%chiusura 2 nov

Dati fino al 30 settembre 2026, dal 10-Q depositato il 29 ottobre 2026

1M: +6,2%
3M: -7,0%

Just reported

Q3 2026 results

From Indivior Pharmaceuticals's results release of 29 ottobre 2026; its quarterly report has since been filed.

Revenue
Actual
356M USD
+13% y/y
+3,8% q/q
Guided
—
No guide given
EPS, GAAP
Actual
1,12 USD
+239% y/y
+14% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
180M USD
+319% y/y
+13% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue1,295B USD – 1,365B USD+7,3% y/y Raised +6,4%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Drug Manufacturers Specialty and Generic

Graded A or B and worth $2B or more: A first, then the largest.

All 78 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Come guadagna

SUBLOCADE monthly buprenorphine injections74%
Sublingual buprenorphine medicines25%

Le quote di ricavo sono stime per six months ended June 30, 2026, non cifre tratte da un documento depositato.

Compete con

CAMXCamurus
Braeburn
ALKSAlkermes
C
Dimensione
7,9B USD
Margine
-0,0%

Che cosa vende4

SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.

Chi lo compra4

Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.

Su cosa si regge e cosa potrebbe romperlo

Da che cosa dipende l'attività

1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
2The United States accounted for 85% of net revenue (2025, high).
3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).

Che cosa potrebbe andare storto

1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.

Bilanci completi →

Informazioni su Indivior Pharmaceuticals, Inc.

Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.

Sede: Richmond, Virginia, United States
Fondata nel: 2014
Quotata su: Nasdaq
Chiusura dell'esercizio: December 31

Costruito dai documenti depositati da Indivior Pharmaceuticals, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.

Just reported